|
| 37163358 | Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. | | 2023 |
| 37592106 | Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. | | 2023 |
| 36681151 | Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience. | | 2023 |
| 34871550 | Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. | Lancet Oncology, The | 2022 |
| 35846441 | Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production. | Heliyon | 2022 |
| 36151090 | I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients. | Blood Cancer J | 2022 |
| 36190955 | Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation. | Molecular Cancer Therapeutics | 2022 |
| 35256844 | Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States. | Patient Preference and Adherence | 2022 |
| 35248777 | Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation. | Transplantation and Cellular Therapy | 2022 |
| 35133221 | Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2â¿¿MM-014 trial. | Leuk Lymphoma | 2022 |
| 34529955 | Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. | Lancet Haematol | 2021 |
| 35846096 | Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. | | 2021 |
| 35844693 | Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. | | 2021 |
| 35844688 | Patient-reported outcomes following autologous stem cell transplant for patients with multiple myeloma. | EJHaem | 2021 |
| 34180331 | Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma. | Leukemia and Lymphoma | 2021 |
| 33735504 | Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. | Cancer | 2021 |
| 33626253 | Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. | New England Journal of Medicine | 2021 |
| 33571168 | Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. | JCI insight | 2021 |
| 33985401 | Selinexor for the treatment of patients with previously treated multiple myeloma. | Expert Review of Hematology | 2021 |
| 34137024 | Immune tolerance with combined allogeneic haplo-identical haematopoietic stem cell transplant and renal transplant. | British Journal of Haematology | 2021 |
| 33442665 | Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort. | JNCI Cancer Spectrum | 2021 |
| 33358693 | Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2021 |
| 32974944 | Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. | American Journal of Hematology | 2021 |
| 33125764 | A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. | American Journal of Hematology | 2021 |
| 33112184 | Efficacy and safety of weekly carfilzomib (70â¿¿mg/m), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. | Leukemia and Lymphoma | 2021 |
| 34435374 | Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma. | Am J Hematol | 2021 |
| 34489684 | Inflammatory Biomarkers Aid in Diagnosis of Dementia. | Frontiers in Aging Neuroscience | 2021 |
| 34488662 | Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. | BMC Cancer | 2021 |
| 31359240 | Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. | Investigational New Drugs | 2020 |
| 32376855 | Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. | Leukemia | 2020 |
| 31588567 | Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. | Br J Haematol | 2020 |
| 32245742 | Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. | Clinical Lymphoma, Myeloma and Leukemia | 2020 |
| 32108443 | Once-weekly (70 mg/m ) vs twice-weekly (56 mg/m ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. | Cancer Medicine | 2020 |
| 32160077 | Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications. | Journal of Clinical Oncology | 2020 |
| 32094461 | Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. | Leukemia | 2020 |
| 32152297 | Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. | Blood Cancer Journal | 2020 |
| 32204955 | Targeting MCL-1 in hematologic malignancies: Rationale and progress. | Blood Reviews | 2020 |
| 32928795 | Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. | Clinical Cancer Research | 2020 |
| 32594908 | Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs. | Genome Biol | 2020 |
| 32682484 | Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. | Lancet, The | 2020 |
| 33166401 | Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. | Blood advances | 2020 |
| 33271097 | Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. | Lancet Oncology, The | 2020 |
| 32838323 | Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. | Lancet Rheumatol | 2020 |
| 32606424 | B-cell maturation antigen expression across hematologic cancers: a systematic literature review. | Blood Cancer Journal | 2020 |
| 31042825 | Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. | New England Journal of Medicine | 2019 |
| 30478094 | Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. | Blood | 2019 |
| 31142508 | A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. | Clinical Cancer Research | 2019 |
| 31090915 | Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. | British Journal of Haematology | 2019 |
| 31021005 | Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. | American Journal of Hematology | 2019 |
| 31101891 | A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma. | Bone Marrow Transplantation | 2019 |